PHARMACOECONOMIC ANALYSIS OF ANTIHYPERTENSIVE PREPARATIONS, PRESCRIBED TO PENSION AGE PATIENTS WITH ARTERIAL HYPERTENSION RESIDING IN DONBASS
ObjectiveTo estimate the expenses on the pharmacotherapy of pension age patients with arterial hypertension, taking part in the programme of increase of compliance, using the method of pharmacoeconomic analysis “cost-effectiveness” of antihypertension drugs Russian and foreign-produced.Material and methodsThe treatment of 114 pension age patients with arterial hypertension residing in Donbass has been analyzed. All patients received combined pharmacotherapy: 42 people received Russian medical preparations and imported drugs (pharmacotherapy of such patients has not been subjected to pharmacoeconomic analysis). The remaining 72 patients took only Russian medical preparations (40 people), or only imported drugs (32 people). In these patients, diaries were analyzed in which they recorded medication and blood pressure levels. For the pharmacoeconomic analysis, a cost-effectiveness analysis was selected.Results and discussionThe following combinations of pharmacological groups were used in 72 patients, who took only Russian or only imported antihypertensive drugs: angiotensin-converting enzyme inhibitors + diuretic (30 people); beta-blockers + calcium channel blockers (19 people); angiotensin receptor blockers + diuretic (23 people).Analysis of individual diaries showed that patients regularly took antihypertensive drugs (as prescribed by a physician), and self-monitoring of treatment provided an effective reduction in blood pressure.The pharmacoeconomic cost-effectiveness analysis showed that with an increase in the cost of imported drugs in pension age patients with arterial hypertension, systolic blood pressure decreases more pronounced (R = 0.678, with p = 0.022). In the group of patients taking Russian generics, no association of systolic blood pressure reduction with the cost of the drug was detected (R = 0.483, with p = 0.131). The cost-effectiveness ratio for imported drugs is 68.8 ± 33.4 rubles / mmHg, and for Russian generics it is 11.7 ± 8.3 rubles / mmHg. Art.ConclusionFor the ﬁ rst time, with the direct participation of a pharmacist, a programme to improve compliance of pension age patients with arterial hypertension was organized in Donbass. The advice of the pharmacist to the visitors of the pharmacy in terms of compliance with the regimen of antihypertensive drugs, as well as the acquisition of drugs by patients, in accordance with their ﬁ nancial capabilities, made it possible to optimize the treatment of patients with arterial hypertension (increased compliance and achieving target blood pressure). Pharmacoeconomic analysis of antihypertensive drugs, prescribed to pension age patients with arterial hypertension residing in Donbass, using the cost-effectiveness method, showed that the use of Russian and imported drugs by patients provides comparable antihypertensive efﬁ cacy; at the same time, signiﬁ cantly lower costs of treatment are observed, when using drugs, manufactured in Russia.